

PALM INTRANET

Day : Monday
Date: 3/26/2007

Time: 09:17:44

Inventor Information for 10/596386

Inventor Name	City	State/Country
<u>GUILLEMONT, JEROME EMILE, GEORGES</u>	ANDE	FRANCE
<u>PASQUIER, ELISABETH THERESE JEANNE</u>	LE NEUBOURG	FRANCE

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity/Reexam](#)[Foreign](#)Search Another: Application# or Patent# PCT / / or PG PUBS # Attorney Docket # Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	344	544/96.ccls.	USPAT	OR	OFF	2007/03/26 09:41
L2	939	(514/228.8,233.8,233.5).ccls.	USPAT	OR	OFF	2007/03/26 09:42
L3	1216	I1 I2	USPAT	OR	OFF	2007/03/26 09:41
L5	5	544/96.ccls.	US-PGPUB	OR	OFF	2007/03/26 09:41
L6	180	(514/228.8,233.8,233.5).ccls.	US-PGPUB	OR	OFF	2007/03/26 09:42
L7	184	I5 I6	US-PGPUB	OR	OFF	2007/03/26 09:42

17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 22 23
chain bonds :
8-17 11-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16 18-23 18-19 19-20 20-21 21-22 22-23
exact/norm bonds :
5-7 6-10 7-8 8-9 9-10 18-23 18-19 19-20 20-21 21-22 22-23
exact bonds :
8-17 11-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 18 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 25:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:12:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED

20 ITERATIONS

0 ANSWERS

Habte

03/26/2007

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 132 TO 668
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:12:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 378 TO ITERATE

100.0% PROCESSED 378 ITERATIONS 31 ANSWERS
SEARCH TIME: 00.00.01

L3 31 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 08:12:42 ON 26 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 25 Mar 2007 (20070325/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s l3
L4 2 L3
=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:150180 CAPLUS
 DOCUMENT NUMBER: 146:229198
 TITLE: Preparation of quinoline derivatives as antibacterial agents
 INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Guillemont, Jerome Emile Georges; Pasquier, Elisabeth
 Therese Jeanne
 Janssen Pharmaceutica N.V., Belg.
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 61pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014934	A2	20070208	WO 2006-EP64847	20060731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TO, BM, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM PRIORITY APPL. INFO.: EP 2005-107155 A 20050803 OTHER SOURCE(S): MARPAT 146:229198 GI				

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula I & II (R1

= H, halo(alkyl), cyano, etc.; R2 = H, halo, mercapto, etc.; R3 = alkyl, (un)substituted aryl(alkyl) or heterocycl(alkyl); R4 = H, alkyl or benzyl; R5 = H, halo(alkyl), (aryl)alkyl, etc.; R6 = H, alkyl, (un)substituted aryl or heterocycl(alkyl); R7 = H or alkyl; R8 = oxo; Z = CH2 or C=O; m = 1-4; n = 1-5, a pharmaceutically acceptable acid or base addition salt, a quaternary amine, a stereochem. isomeric form, a tautomeric form or a N-oxide form thereof. For example, III was provided in a multi-step synthesis starting from the reaction of benzenepropanoyl chloride with 4-bromobenzenamine. I showed antibacterial activity in Microtitre plate assay.

IT 861708-88-5P 861709-05-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinoline deriva. as antibacterial agents)
 RN 861708-88-5 CAPLUS
 CN Quinoline, 6-chloro-2-methoxy-3-[(R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861709-05-9 CAPLUS
 CN Quinoline, 6-bromo-2-methoxy-3-[(R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 861708-84-1P 861708-86-3P 861708-90-9P
 861708-94-3P 861708-96-5P 861708-98-7P
 861709-00-4P 861709-02-6P 861709-07-1P
 861709-08-2P 861709-09-3P 861709-10-6P
 861709-11-7P 861709-12-8P 861709-13-9P
 924621-40-9P 924621-41-0P 924621-42-1P
 924621-43-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinoline deriva. as antibacterial agents)
 RN 861708-84-1 CAPLUS
 CN Quinoline, 6-bromo-2-methoxy-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861708-86-3 CAPLUS
 CN Quinoline, 6-bromo-3-[(S)-(4-chlorophenyl)[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 861708-90-9 CAPLUS
 CN 2H-1,3-Oxazin-6-ylmethyl-6-(1-naphthalenyl)-2-methoxy-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

• I⁻

RN 861708-94-3 CAPLUS
 CN Quinoline,
 2-methoxy-6-phenyl-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 861708-96-5 CAPLUS
 CN Quinoline,
 6-chloro-2-methoxy-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 861709-02-6 CAPLUS
 CN Quinoline,
 6-(2-furanyl)-2-methoxy-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 861709-07-1 CAPLUS
 CN Quinoline,
 6-bromo-2-methoxy-3-[(phenyl[(6R)-tetrahydro-3-methyl-6-phenyl-2H-1,3-oxazin-6-yl]methyl)- (9CI) (CA INDEX NAME)



RN 861709-08-2 CAPLUS
 CN Quinoline,
 2-methoxy-6-phenyl-3-[(R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 861709-09-3 CAPLUS


Habte

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 861708-98-7 CAPLUS
 CN Quinoline, 2,6-dimethoxy-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 861709-00-4 CAPLUS
 CN Quinoline,
 2-methoxy-6-methyl-3-[(S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Quinoline, 2,6-dimethoxy-3-[(R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861709-10-6 CAPLUS
 CN Quinoline,
 2-methoxy-6-methyl-3-[(R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 861709-11-7 CAPLUS
 CN Quinoline,
 6-(2-furanyl)-2-methoxy-3-[(R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


03/26/2007

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861709-12-8 CAPLUS
 CN Quinoline, 6-bromo-3-[(R)-(4-chlorophenyl)[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 861709-13-9 CAPLUS
 CN 2H-1,3-Oxazin, 6-[(R)-(6-chloro-2-methoxy-3-quinolinyl)phenylmethyl]tetrahydro-3,3-dimethyl-6-(1-naphthalenyl)-, iodide, (6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

● I⁻

RN 924621-40-9 CAPLUS
 CN 2H-1,3-Oxazin, 6-[(R)-(6-bromo-2-methoxy-3-quinolinyl)phenylmethyl]tetrahydro-3,3-dimethyl-6-(1-naphthalenyl)-, iodide (1:1), (6R)-rel- (CA INDEX NAME)


Relative stereochemistry.

● I⁻

RN 924621-41-0 CAPLUS
 CN 2H-1,3-Oxazin, 6-[(S)-(6-bromo-2-methoxy-3-quinolinyl)phenylmethyl]tetrahydro-3,3-dimethyl-6-(1-naphthalenyl)-, iodide (1:1), (6R)-rel- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

● I⁻

RN 924621-42-1 CAPLUS
 CN 2H-1,3-Oxazin, 6-[(R)-(6-bromo-2-methoxy-3-quinolinyl)phenylmethyl]-3-ethyltetrahydro-3-methyl-6-(1-naphthalenyl)-, iodide (1:1), (6R)-rel- (CA INDEX NAME)


Relative stereochemistry.

● I⁻

RN 924621-43-2 CAPLUS
 CN 2H-1,3-Oxazin, 6-[(S)-(6-bromo-2-methoxy-3-quinolinyl)phenylmethyl]-3-ethyltetrahydro-3-methyl-6-(1-naphthalenyl)-, iodide (1:1), (6R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

● I⁻

own
work

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2005:696905 CAPLUS
 DOCUMENT NUMBER: 143:194012
 TITLE: Preparation of oxazinylbenzylquinolines as mycobacterial inhibitors.
 INVENTOR(S): Guillemont, Jerome Emile Georges; Pasquier, Elisabeth
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070924	A1	20050804	WO 2005-EP50267	20050121
WO 2005070924	A8	20060511		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SM

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG.

AU 2005206330 A1 20050804 AU 2005-206330 20050121
 CA 2553266 A1 20050804 CA 2005-2553266 20050121
 EP 1711492 A1 20061018 EP 2005-701586 20050121

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1910177 A 20070207 CN 2005-80002679 20050121
 NO 2006003747 A 20060822 NO 2006-3747 20060822
 US 2004-538768P P 20040123


PRIORITY APPLN. INFO.:
 WO 2005-EP50267 W 20050121

OTHER SOURCE(S): MARPAT 143:194012
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I, II]; R1 = H, halo, haloalkyl, cyano, OH, Ar, Het, alkyl, alkoxy, alkylthio, alkoxyalkyl, alkylthioalkyl, aralkyl, diarylalkyl; p = 1-4; R2 = H, OH, SH, alkoxy, alkoxyalkoxy, alkylthio, mono or dialkylamino, piperidinyl, morpholino, thiomorpholino, (alkyl)piperazinyl;

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861708-88-5 CAPLUS
 CN Quinoline,
 6-chloro-2-methoxy-3-[(R)-phenyl]-(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-ylmethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861708-90-9 CAPLUS
 CN 2H-1,3-Oxazin-6-ylmethyl-6-(1-chloro-2-methoxy-3-quinolinyl)phenylmethyl-tetrahydro-3,3-dimethyl-6-(1-naphthalenyl)-, iodide, (6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 R3 = alkyl, Ar, aralkyl, Het, Het-alkyl; R4 = H, alkyl, benzyl; R5 = H, halo, haloalkyl, OH, Ar, alkyl, alkoxy, alkylthio, alkoxyalkyl, alkylthioalkyl, Aralkyl, diarylalkyl; 2 vicinal R5 = atoms to form a fused

Ph ring; n = 1-5; R6 = H, alkyl, Ar, Het; R7 = H, alkyl; R8 = O; or R7R8

CH:CHN; 2 = CH2, CO; Ar = (substituted) Ph, naphthyl, acenaphthyl, tetrahydronaphthyl, Het = (substituted) N-phenoxy-piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, benzothiazolyl, benzothienyl, etc.), were prepd. Thus, title compd.

(III) (prepd. via cyclocondensation of paraformaldehyde with the corresponding aminoalc.) showed pIC50 = 8.5 against M. smegmatis ATCC607.


IT 861708-84-1P 861708-86-3P 861708-88-5P
 861708-90-9P 861708-92-1P 861708-94-3P
 861708-96-5P 861708-98-7P 861709-00-4P
 861709-02-6P 861709-05-9P 861709-07-1P
 861709-08-2P 861709-09-3P 861709-10-6P
 861709-11-7P 861709-12-8P 861709-13-9P
 861709-14-0P 861709-15-1P 861709-16-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazinylbenzylquinolines as mycobacterial inhibitors)

RN 861708-84-1 CAPLUS
 CN Quinoline, 6-bromo-2-methoxy-3-[(S)-phenyl]-(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-ylmethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 861708-86-3 CAPLUS
 CN Quinoline, 6-bromo-2-methoxy-3-[(S)-phenyl]-(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-ylmethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861708-92-1 CAPLUS
 CN 2H-1,3-Oxazin-2-one,
 6-[(R)-6-bromo-2-methoxy-3-quinolinyl]phenylmethyl-6-(2,4-difluorophenyl)-3-ethyltetrahydro-, (6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 861708-94-3 CAPLUS
 CN Quinoline,
 2-methoxy-6-phenyl-3-[(S)-phenyl]-(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-ylmethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 861708-96-5 CAPLUS
CN Quinoline,
6-chloro-2-methoxy-3-((S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 861708-98-7 CAPLUS
CN Quinoline, 2,6-dimethoxy-3-((S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 861709-07-1 CAPLUS
CN Quinoline,
6-bromo-2-methoxy-3-((R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)



RN 861709-08-2 CAPLUS
CN Quinoline,
2-methoxy-6-phenyl-3-((R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861709-09-3 CAPLUS
CN Quinoline, 2,6-dimethoxy-3-((R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Hatte

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 861709-00-4 CAPLUS
CN Quinoline,
2-methoxy-6-methyl-3-((S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861709-02-6 CAPLUS
CN Quinoline,
6-(2-furanyl)-2-methoxy-3-((S)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 861709-05-9 CAPLUS
CN Quinoline, 6-bromo-2-methoxy-3-((R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 861709-10-6 CAPLUS
CN Quinoline,
2-methoxy-6-methyl-3-((R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861709-11-7 CAPLUS
CN Quinoline,
6-(2-furanyl)-2-methoxy-3-((R)-phenyl[(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl]methyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 861709-12-8 CAPLUS

03/26/2007


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Quinoline, 6-bromo-3-[(R)-(4-chlorophenyl)][(6R)-tetrahydro-3-methyl-6-(1-naphthalenyl)-2H-1,3-oxazin-6-yl)methyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861709-13-9 CAPLUS
 CN 2H-1,3-Oxazin-6-yl-[(R)-(6-chloro-2-methoxy-3-quinolinyl)phenylmethyl]tetrahydro-3,3-dimethyl-6-(1-naphthalenyl)-, iodide, (6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



• I⁻

RN 861709-14-0 CAPLUS
 CN 2H-1,3-Oxazin-2-one, 6-[(R)-(6-bromo-2-methoxy-3-quinolinyl)phenylmethyl]-6-(2,4-difluorophenyl)-3-ethyltetrahydro-, (6S)-rel- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Relative stereochemistry.



RN 861709-15-1 CAPLUS
 CN Quinoline, 3-[(S)-[(6R)-6-(2-furanyl)tetrahydro-3-methyl-2H-1,3-oxazin-6-yl]phenylmethyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 861709-16-2 CAPLUS
 CN Quinoline, 3-[(R)-[(6R)-6-(2-furanyl)tetrahydro-3-methyl-2H-1,3-oxazin-6-yl]phenylmethyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.